A Randomised, Double-Blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN, AZD2171) in Combination With 5-Fluorouracil, Leucovorin [folinic-acid], and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer.

Trial Profile

A Randomised, Double-Blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN, AZD2171) in Combination With 5-Fluorouracil, Leucovorin [folinic-acid], and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 22 Apr 2017

At a glance

  • Drugs Cediranib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms HORIZON-III
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 18 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov
    • 30 Jul 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Jun 2014 to 1 Dec 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top